Related by context. Frequent words. (Click for all words.) 59 Ore Pharmaceuticals 59 MDS Analytical Technologies 58 senior subordinated convertible 57 pension curtailment 56 convertible subordinated notes 56 QLT USA 55 CompX 55 Adjusted EBITDA excludes 55 OTTI charges 54 Significant Items 54 convertible promissory notes 54 FSP APB #-# 54 items affecting comparability 54 intangibles amortization 54 Restructuring Charges 54 Discontinued Operations 54 OTTI charge 54 Goodwill Impairment 54 CoGenesys 53 Normalized EBITDA 53 mandatorily redeemable preferred 53 debt extinguishment 53 unrealized depreciation 53 Including discontinued operations 53 QSI segment 53 HLTH Corporation 52 antidilutive 52 unallocated expenses 52 Adjusted diluted 52 Enzon Pharmaceuticals 52 discount accretion 52 YTD Fiscal 52 Senior Convertible Notes 52 Pro forma net 52 Coley Pharmaceutical Group 52 convertible subordinated 52 Incyte Corporation 52 Impairment Charges 52 items impacting comparability 52 Enzo Biochem 52 unamortized debt 51 AVEO Pharmaceuticals Inc. 51 Business Combinations 51 BioVeris 51 Pro forma diluted 51 MDS Pharma Services 51 equity investee 51 condensed consolidated 51 Facet Biotech Corporation 51 income allocable 51 - Income [022] 51 Segment Profit 51 Targanta 51 Neurovascular 51 % Convertible Subordinated 51 Subsequent Events 51 Adjusted Diluted EPS 51 - Income [025] 51 junior subordinated debentures 51 - -Semiconductor Manufacturing International 51 Based Compensation Expense 50 discontinued operations 50 Par Pharmaceutical Companies 50 excludes amortization 50 - Income [009] 50 Pharmion Corporation 50 Core FFO 50 convertible subordinated debentures 50 VIEs 50 Helicos BioSciences 50 purchased intangible assets 50 b Represents 50 dilutive securities 50 acquired intangible assets 50 - -Punishes 50 unsecured convertible 50 Valentis 50 Diluted EPS 50 early extinguishment 50 temporary impairment OTTI 50 - Net [013] 50 - Income [030] 50 - Income [032] 50 Convertible Debt 50 - Ifreshly dug 50 Facet Biotech 50 PDL BioPharma 50 Fully diluted earnings 50 - -Walshaw 50 Enzon 50 Genaissance 50 Bairnco 50 SFAS #R 50 - Income [027] 49 Exchangeable Senior 49 NextRx 49 equity investees 49 non recurring 49 temporary impairments 49 -CSMMU 49 - Net [040]